Financhill
Buy
61

GH Quote, Financials, Valuation and Earnings

Last price:
$50.56
Seasonality move :
-9.62%
Day range:
$50.83 - $52.46
52-week range:
$20.14 - $53.42
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.17x
P/B ratio:
32.59x
Volume:
1.8M
Avg. volume:
2.2M
1-year change:
85.77%
Market cap:
$6.4B
Revenue:
$739M
EPS (TTM):
-$3.39

Analysts' Opinion

  • Consensus Rating
    Guardant Health has received a consensus rating of Buy. The company's average rating is a Buy based on 15 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $59.66, Guardant Health has an estimated upside of 16.32% from its current price of $51.29.
  • Price Target Downside
    According to analysts, the lowest downside price target is $47.00 representing 100% downside risk from its current price of $51.29.

Fair Value

  • According to the consensus of 18 analysts, Guardant Health has 16.32% upside to fair value with a price target of $59.66 per share.

GH vs. S&P 500

  • Over the past 5 trading days, Guardant Health has overperformed the S&P 500 by 2.19% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Guardant Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Guardant Health has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Guardant Health reported revenues of $203.5M.

Earnings Growth

  • Guardant Health has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Guardant Health reported earnings per share of -$0.77.
Enterprise value:
6.8B
EV / Invested capital:
--
Price / LTM sales:
8.17x
EV / EBIT:
--
EV / Revenue:
8.75x
PEG ratio (5yr expected):
-2.52x
EV / Free cash flow:
-22.21x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$474.8M
Return On Assets:
-27.11%
Net Income Margin (TTM):
-53.82%
Return On Equity:
-8518.58%
Return On Invested Capital:
-39.31%
Operating Margin:
-54.57%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $482.2M $603.7M $774M $168.5M $203.5M
Gross Profit $304.7M $364.5M $474.8M $103.2M $128.7M
Operating Income -$555.1M -$530.4M -$455M -$99.7M -$111M
EBITDA -$621.8M -$414.2M -$370.7M -$103.2M -$83.8M
Diluted EPS -$6.49 -$3.92 -$3.39 -$0.94 -$0.77
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $2B $1.1B $1.1B $1.3B $927M
Total Assets $2.3B $2.1B $1.5B $1.7B $1.3B
Current Liabilities $95.5M $228.8M $204.2M $220M $225.8M
Total Liabilities $1.4B $1.6B $1.6B $1.6B $1.6B
Total Equity $906.4M $533M -$44.6M $68.3M -$250.8M
Total Debt $1.1B $1.1B $1.1B $1.1B $1.1B
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations -$355.3M -$280.8M -$272.3M -$30.3M -$62.7M
Cash From Investing $196.2M $711.1M $13.5M $28.1M $302.9M
Cash From Financing -$189.9M $477.2M -$66.8M -$1.1M -$66.9M
Free Cash Flow -$417.6M -$300.7M -$304.9M -$37.2M -$67.1M
GH
Sector
Market Cap
$6.4B
$33.5M
Price % of 52-Week High
96.01%
48.01%
Dividend Yield
0%
0%
Shareholder Yield
0.94%
-0.97%
1-Year Price Total Return
85.77%
-33.61%
Beta (5-Year)
1.442
0.621
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $50.77
200-day SMA
Buy
Level $38.25
Bollinger Bands (100)
Buy
Level 40.97 - 48.77
Chaikin Money Flow
Buy
Level 416.4K
20-day SMA
Buy
Level $50.07
Relative Strength Index (RSI14)
Buy
Level 61.92
ADX Line
Buy
Level 17.29
Williams %R
Neutral
Level -35.6784
50-day SMA
Buy
Level $45.77
MACD (12, 26)
Buy
Level 9.61
25-day Aroon Oscillator
Buy
Level 64
On Balance Volume
Neutral
Level 5.9M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-0.8245)
Sell
CA Score (Annual)
Level (-3.7489)
Buy
Beneish M-Score (Annual)
Level (-2.7884)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.4274)
Buy
Piotroski F Score (Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Stock Forecast FAQ

In the current month, GH has received 15 Buy ratings 3 Hold ratings, and 0 Sell ratings. The GH average analyst price target in the past 3 months is $59.66.

  • Where Will Guardant Health Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Guardant Health share price will rise to $59.66 per share over the next 12 months.

  • What Do Analysts Say About Guardant Health?

    Analysts are divided on their view about Guardant Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Guardant Health is a Sell and believe this share price will drop from its current level to $47.00.

  • What Is Guardant Health's Price Target?

    The price target for Guardant Health over the next 1-year time period is forecast to be $59.66 according to 18 Wall Street analysts, 15 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.

  • Is GH A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Guardant Health is a Buy. 15 of 18 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of GH?

    You can purchase shares of Guardant Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Guardant Health shares.

  • What Is The Guardant Health Share Price Today?

    Guardant Health was last trading at $50.56 per share. This represents the most recent stock quote for Guardant Health. Yesterday, Guardant Health closed at $51.29 per share.

  • How To Buy Guardant Health Stock Online?

    In order to purchase Guardant Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Can FUBO Stock Double?
Can FUBO Stock Double?

TV streaming service Fubo (NYSE:FUBO) has seen incredible returns so…

Where Will CoreWeave Stock Be in 1 Year?
Where Will CoreWeave Stock Be in 1 Year?

When CoreWeave (NASDAQ: CRWV) slipped below its $40 IPO price…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
76
MP alert for Jul 11

MP Materials [MP] is down 0.15% over the past day.

Buy
51
NEGG alert for Jul 11

Newegg Commerce [NEGG] is up 52.59% over the past day.

Buy
76
UAL alert for Jul 11

United Airlines Holdings [UAL] is down 4.13% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock